most common bleeding disorder. VWD is clinically heterogeneous and is classified into 3 main categories based on distinct quantitative and qualitative abnormalities in von Willebrand factor (VWF). [2] [3] [4] Type 1 VWD is the most common form (~70%-75% of all cases) and is characterized by a partial quantitative deficiency in functionally normal VWF. Type 3 VWD (~1%-3% of cases) is characterized by a severe quantitative deficiency in VWF together with very low plasma factor VIII coagulant activity (FVIII:C). Type 2 VWD (~20% of cases) is characterized by qualitative deficiencies in VWD and is further subdivided into 2A, 2B, 2M and 2N subtypes.
The fifth Åland Island meeting 2016, which coincided with the 90th anniversary of the first VWD case description by Erik von Willebrand in a 5-year-old girl named Hjördis S from the Åland Islands, brought together experts in VWD to discuss the latest scientific and clinical knowledge on VWD.
| V WF S TRUC TURE AND FUN C TI ON

| Nanoscopic view on VWF structure and Weibel-Palade bodies
Weibel-Palade bodies (WPBs) are storage organelles for VWF in endothelial cells ( Figure 1A ). 5, 6 After its synthesis in the endoplasmic reticulum, VWF pre-pro-proteins undergo cleavage and go on to form multimers. 6 WPBs are first formed in the trans-Golgi network and, as WPBs develop, the stored VWF is assembled into tubules. 6, 7 During maturation of the WPBs, VWF tubules grow and WPBs become elongated and more protein-dense. 6, 8, 9 At the end of this process, other co-stored proteins are also packaged into the WPB granules. 6 Upon stress stimulation, such as injury or inflammation, mature WPBs are transported to the plasma membrane. 6 VWF is then secreted into blood vessels via exocytosis where it structurally rearranges into strings to capture platelets and initiate primary haemostasis. 6 To elucidate the mechanistic details of the WPB life cycle, biogenesis of WPBs was followed using various ultrastructure imaging techniques [10] [11] [12] ( Figure 1B -D). WPBs were first depleted from human umbilical cord venous endothelial cells (HUVECs) by phorbol 12-myristate 13-acetate (PMA) treatment, which induces exocytosis of WPBs. 11 Synthesis of nascent WPBs over time was then followed by visualization of VWF. Confocal microscopy and transmission electron microscopy analyses of immunofluorescence-and immunogoldlabelled VWF, respectively, showed the appearance of newly formed WPB-like structures containing VWF tubules after 4 hours of recovery from PMA treatment. 11 These findings were then confirmed using correlative light and electron microscopy (CLEM), which combines confocal microscopy with conventional transmission electron microscopy, using transfected HUVECs expressing enhanced green fluorescent protein (EGFP)-tagged VWF propeptide 10, 11 ( Figure 1B ).
The CLEM analysis revealed that 4 hours after transfection, early electron-lucent WPBs began to appear and that 6 and 8 hours after transfection they appeared denser and more elongated. The 3D morphology of nascent WPBs was also investigated by electron tomography as well as serial block-face scanning electron microscopy ( Figure 1C-D) , where a focussed ion beam removes layers of sample material in between cycles of scanning electron microscopy imaging. 11, 12 This showed that WPBs are tightly associated with the Golgi through numerous connections during their formation. As
WPBs develop, non-tubular VWFs are delivered from the Golgi to the lumen of the WPBs through these connections and once inside VWFs rearrange into tubules. Interestingly, the WPB-Golgi connections continue to be maintained 8 hours after transfection of the labelled propeptide when dense elongated WPBs are already visible. 11 Findings from this nanostructure imaging study, where WPBs remain closely Golgi-associated until maturation, are in line with results from a separate study using super-resolution microscopy. 13 There are several modes of VWF secretion from mature, stimulated WPBs. 14, 15 Single WPBs can exocytose individually, and F I G U R E 1 Visualizing the life cycle of WPBs at the ultrastructural level. [10] [11] [12] A,
The life cycle of WPBs. B, Correlative light and electron microscopy of nascent WPB formation. C, Serial block-face scanning electron microscopy imaging of WPBs adjacent to (yellow) and connected to (red) the Golgi (green). The nucleus is shown in blue. D, Electron tomography of WPB (green) with numerous connections to the Golgi (yellow). WPB, Weibel-Palade bodies several WPBs may fuse intracellularly to produce large secretory pods prior to release of VWF. 16 Live-cell imaging in HUVECs confirmed that large secretory pods are formed through coalescence of multiple WPBs shortly before secretion. 17 The analysis also revealed that VWF adopts a globular conformation immediately after exocytosis and remains anchored to the cell periphery for structural remodelling to form strings. 17 Under more physiological conditions using a flow chamber, the extension of VWF strings was predominantly observed at the edge of cells, which suggests this structural remodelling process may be facilitated by surface receptors such as integrins. 17 Another mode of secretion is known as the "lingering kiss" where smaller co-stored cargo in WPBs, such as interleukins, is selectively released while VWF is retained intracellularly.
14 Genetic mutations in a discrete region of the VWF gene have been associated with VWD patients who are non-responders or partial responders to desamino-D-arginine vasopressin (DDAVP), which acts to induce VWF secretion from endothelial cells. 18 However, the mechanism underlying the response to DDAVP is likely to be very complex as similar mutations are found in both non-responders and responders. 18 In a cell-based study, these VWF mutations were studied in more detail by their transient expression in HEK293 cells. 19 Key mutant phenotypes included the inability to form mature elongated WPBs, retention of VWF in the endoplasmic reticulum and reduced VWF secretion upon PMA stimulation. These findings suggest that impairment at different stages of the WPB life cycle, including release of VWF and string formation, may play a role in the pathogenesis of VWD. 19, 20 Advances in cell imaging techniques have greatly improved our knowledge of the physiological and pathophysiological processes involved in the storage and release of VWF. Impaired VWF storage, release and string formation seem to be potential pathophysiological mechanisms in VWD.
| V WD EPIDEMI OLOGY AND DIAG NOS TIC S
| Diagnosing type 1 VWD
Although laboratory tests can generally distinguish type 1 VWD from other subtypes, the diagnosis of type 1 VWD remains challenging. Diagnosis of type 1 VWD is complicated by the high frequency of bleeding symptoms in the general population, the overlap of VWF level ranges in non-VWD individuals and VWD patients, and the lack of a strict relationship between VWF level and the severity and frequency of bleeding. [21] [22] [23] The continuous spectrum from severe VWD to non-affected individuals presents difficulties for setting decisional thresholds to distinguish those affected from those not affected. This is evident in the variation in reported prevalence estimates, which span 2-3 orders of magnitude. The prevalence is estimated to be 1 in 100 based on population-based studies and 1 in 1000 or 1 in 10 000 in specialized centres and most review articles.
24-28
The aim of diagnosis should be to achieve a positive clinical outcome after a diagnosis. The outcome of diagnosis can be viewed in terms of diagnostic utility (patient perspective) and diagnostic accuracy (physician perspective). 21 As clinicians, we should pursue a clinically useful diagnosis, which means that the diagnosis should be of some benefit for the patient and not simply be accurate (ie, a diagnosis not biased by high false-positive or false-negative rates). 21 However, this is a particularly difficult task in mild bleeding disorders such as type 1 VWD.
Collaborative studies on large cohorts of patients with mainly type 1 VWD have demonstrated the utility of a bleeding assessment tool (BAT) in diagnosis. [29] [30] [31] [32] In the first of these studies, an international multicentre study (Vicenza BAT study), 29 Figure 2 ).
With these minimal criteria, the Bayesian calculation allows the estimation of the probability of having VWD as 80/100 (80%). 25 Using this approach, 1 in 5 of patients would be incorrectly classified, which can be reduced to 1 in 16 if the minimum criteria are extended to include a family member with VWF:RCo <40 IU dL −1 .
38
Once the minimal criteria for VWD diagnosis have been met, the next step would be to conduct laboratory analysis to characterize the type and severity of VWD, including a DDAVP test when appropriate, and determine the most suitable treatment.
In summary, 90 years after the discovery of VWD, the diagnosis of type 1 VWD is still intriguing. Using a 2-step process for diagnosis, in which minimal criteria are used to select most likely affected individuals (step 1) followed by full laboratory evaluation (step 2), may improve diagnosis of VWD. However, this approach needs to be validated in large cohorts of patients (adults and children) with various types of VWD. The percentage of patients with type 1 VWD (25%) was lower than previous estimates (~75%). 40 This may be due to the stringent inclusion criteria (VWF <30 IU dL −1 ) and the extensive identification of type 2 VWD in the CMRW cohort, which could otherwise have been classified as type 1 VWD. This is consistent with a European study in patients with type 1 VWD in which one-third of patients could have been reclassified as having type 2 VWD. 35 Data from the CRMW are generally consistent with those from a multicentre Spanish study. 46 The percentage of patients with type 1 and type 3 VWD were similar in the CRMW and Spanish studies, although there was some variation in the distribution of type 2 subtypes. 45, 46 Of the 167 index cases with type 1 VWD, 88 (53%) had type 1 mutations associated with a decreased synthesis/secretion of VWF, 33 (20%) exhibited mutations inducing an accelerated VWF clearance, 6 (3.5%) had propeptide cleavage site mutations, and 34 (20%) exhibited heterozygous mutations and were considered as type 3 carriers; no mutation was found in 6 type 1 VWD patients (3.5%). 45 In the 54 type 3 VWD patients, 61 distinct sequence variations were identified that were novel mutations in two-thirds of cases. These sequence variations were spread over the VWF gene, with a predominance at the N-terminal part of VWF (D domains), and consisted 
| Genetic diagnostics of VWD
F I G U R E 4
| Diagnosis in the United States
| TRE ATMENT OF V WD
| Towards pharmacokinetic population models for VWD: A lot "To WiN"?
Interindividual variation in the pharmacokinetic (PK) parameters of replacement FVIII in patients with haemophilia A is well documented. 47, 48 This variation has stimulated interest in developing PK-guided treatment regimens to optimize the treatment of patients with haemophilia A in the prophylactic setting, 49, 50 although the use of this approach in the perioperative setting, beyond determination of presurgery FVIII in vivo recovery (IVR), has received less attention. PK-guided dosing of VWF/FVIII concentrates has been shown to be effective and safe in patients with VWD undergoing surgery. 51, 52 However, little is known about the PK parameters during surgery in patients with VWD and the correlation between pre-and postsurgery IVR is weak. 53 The "patient tailored pharmacokinetic-guided dosing of clotting factor concentrates in bleeding disorders (OPTI-CLOT)" study group is a multinational collaboration that aims to develop PK-guided perioperative treatment strategies for patients with bleeding disorders. The OPTI-CLOT studies are using perioperative data from clinical studies to construct a perioperative population PK model that can facilitate PK-guided iterative adaptive Bayesian dosing. During this procedure, individual PK parameters are iteratively updated by combining PK information (eg, dose, concentration, time) from the individual patient with a priori PK information from the population.
To date, PK modelling has been applied to perioperative data from a Dutch retrospective study in patients with haemophilia A 54 and PK modelling of perioperative VWD data is currently underway.
In the retrospective analysis of 119 haemophilia A patients undergoing 198 surgical procedures in the Netherlands, 45% of FVIII plasma concentrations were below the target range during the first 24 hours after surgery and 75% of the plasma concentration were above the target range after 6 days of hospitalization during perioperative management with FVIII concentrates 54 ( Figure 6 ). In addition, 55 who participated in the Dutch study. 54 The model incorporated variations in PK parameters; eg, clearance decreased with increasing age (P < .01), increased in cases with blood group O (26%; P < .01), and there was a small decrease during major surgical procedures (7%; P < .01). The final PK model showed a good agreement between FVIII concentrations predicted by the model and those assessed by laboratory measurements. 55 An ongoing, randomized controlled trial F I G U R E 6 Achieved perioperative FVIII levels in a Dutch study in patients receiving clotting factor replacement therapy. 54 shown promise in patients with haemophilia A, and data from patients with VWD will soon be available.
| Surgery in VWD
Bleeding is a major surgical complication and is associated with mor- 61 For monitoring, FVIII:C seems to be more important than VWF:RCo. 61 The parallel decay of VWF:RCo and FVIII:C Tranexamic acid was also recommended by the EHTSB as a valuable adjunctive agent that may be used concomitantly with concentrates in patients with VWD undergoing surgery, particularly those involving mucous membranes. 61 The perioperative management of patients with VWD can be challenging. Current treatment strategies are effective and will often include perioperative treatment with a factor concentrate. However, the dosing and monitoring of a given factor concentrate should be based on the properties of that concentrate and in accordance with its prescribing information, achieving critical target levels, but avoiding sustained excessive FVIII:C levels.
| Surgery in the United States
PK analysis to guide dosing is not always performed and is generally considered to be of academic interest. DDAVP is often used if the patient is responsive and combined with factor concentrate as required.
When DDAVP is used, it is important to monitor sodium levels to avoid water intoxication, particularly when fluid replacement during surgery is high. However, combination therapy is not the standard of care in the United States and most institutions only use factor concentrates.
Achieving haemostasis during surgery is the most crucial factor and should take precedence over the current "over-anxiety" about VWF and FVIII levels during surgery and potential thrombosis. 
| Treatment in the United States
| ANG I OG ENE S IS IN V WD
| VWF and angiodysplasia
The prevention and treatment of GI bleeding due to angiodysplasia is an important unresolved problem in the management of VWD [64] [65] [66] [67] [68] Gastrointestinal bleeding due to angiodysplasia is common in the elderly, with incidences ranging from 2.6% to 6.2% in the general population. 69, 70 Angiodysplasia-related GI bleeding is also a welldocumented complication of VWD, although it occurs more frequently at a younger age and almost exclusively in patients lacking high molecular weight multimers (HMWMs). 65, 71, 72 In a 2-year, prospective study of 107 patients, GI bleeding was much more frequent in patients with VWD characterized by a lack of HMWMs (type 2A) compared with type 2M VWD (Figure 8 ).
TA B L E 1 Guidelines on the dosing and monitoring of VWD patients undergoing surgery
Indirect evidence implicating a lack of HMWMs in angiodysplasiarelated GI bleeding in VWD has come from studies in acquired von ) and a longer duration of treatment (4.23 vs 1.93 days)
were required for the treatment of GI bleeds compared with bleeds at other sites. 78 A similar picture has emerged in studies evaluating VWF/ FVIII concentrates in secondary prophylaxis of recurrent GI bleeding, which have demonstrated the efficacy of VWF/FVIII concentrates but with lower efficacy than at other bleeding sites. 67, 68 In the largest published prophylaxis study, the VWD Prophylaxis Network retrospectively evaluated the efficacy of secondary prophylaxis with VWF/ FVIII concentrates in 59 patients with clinically severe VWD that were unresponsive to other treatments. 79 Recurrent GI bleeding and epistaxis were the most common reasons to initiate prophylaxis, with each accounting for 23.6% (13/55) of cases. 79 Although the number of GI bleeds occurring during prophylaxis was significantly reduced, the percentage reduction in bleeding frequency (49%) was lower than that achieved for joint bleeding (86%). In summary, the prevention and treatment of GI bleeding due to angiodysplasia is an unresolved problem in the management of VWD patients. VWF/FVIII concentrates remain the mainstay therapy for the treatment of GI bleeds. Other strategies, such as rVWF and antiangiogenic drugs, may have a future role in the prevention and treatment of GI bleeding due to angiodysplasia, but need further exploration.
| Reproductive tissue alterations in VWD
Women with VWD are at increased risk of bleeds during the menstrual cycle and during pregnancy. 81 The most common symptom is menorrhagia (heavy menstrual bleeding), which is estimated to affect 32%-100% of women with VWD. 23, 81 Although VWF levels are known to rise in pregnancy, levels in women with VWD remain significantly lower than in their healthy counterparts. 81 Thus, women with VWD are at increased risk of bleeding complications associated with pregnancy and childbirth.
A study conducted in pregnant women with type 1 or type 2 VWD investigated management of VWD during pregnancy. For inclusion in the study, patients had to have had at least 2 previous bleedingassociated miscarriages or were experiencing bleeding during an on- 
| V WF INHIB ITOR S
| Detecting inhibitors in VWD: an academic question?
Anti-VWF inhibitors are a rare complication of replacement therapy that negates the haemostatic response to infused VWF concentrates. 86 Inhibitors develop in an estimated 5.8%-9.5% of patients with type 3 VWD and have very rarely been reported in patients with other VWD types. 86, 87 In a retrospective analysis of the Italian Association of Hemophilia Centers (AICE), 96 of 1650 VWD patients had type 3 VWD (5.8%). Anti-VWF inhibitors were identified in 6 type 3 VWD patients, which correspond to 6.2% (6/96) "mute" regions of VWF molecules that cannot be identified with functional assays. An assay to test anti-VWF antibodies using a sandwich ELISA (Ex-VWF-Plasma-HRP goat anti-human IgG-IgM) appears to be more sensitive than functional assays. 95 The outcome of an ongoing initiative of an ISTH subcommittee on VWF may lead to a more standardized approach to laboratory measurement of VWF inhibitors.
In most reported cases, antibody development is heralded by poor clinical response to replacement therapy accompanied by lower than expected recovery of VWF with the absence of the delayed and sustained raise of FVIII (secondary response to VWF). In cases where inhibitor titre is relatively low, it is not difficult to treat soft-tissue bleeds and to prevent bleeding in surgery. In patients with high-titre inhibitors, replacement therapy is not only ineffective, but it may also trigger life-threatening anaphylactic reactions associated with activation of the complement system. 96 A rise in antibody levels is usually seen 5-10 days after replacement therapy with VWF concentrates, with features typical of a secondary response to a foreign antigen. Recombinant FVIII (no VWF) was effective in a type 3 patient with inhibitors undergoing emergency abdominal surgery. 97 Other possible therapeutic approaches are recombinant activated factor VII (rFVIIa) or a combination of rFVIII and rFVIIa. [98] [99] [100] However, the use of rFVIII and rFVIIa in combination should take into account the possibility of thrombosis.
100
The 3WINTERS-IPS study-type 3 VWD International Registries and Inhibitor Prospective Study (3WINTERS-IPS, 2011-2018) has been set up to record clinical and laboratory data on a large cohort of at least 250 type 3 VWD patients at a network of European and
Iranian centres. 101 The study comprises 3 phases (Figure 9 ). In the first phase, ~250 type 3 patients were retrospectively identified.
In the second phase, the diagnosis will be confirmed by centralized Stockholm. We collected DNA in VWD families and found exon 18 mutation in those with bleeding symptoms in Family S and 2 other families as well as in a 2-year-old boy with severe VWD (homozygote) and his parents (heterozygotes). 102, 106 One cytosine deletion in exon 18 was detected in all the families. Linkage analysis and genealogical studies suggest that the deletion in these families probably has a common origin also with the Swedish patients.
Pier Mannucci concluded by paying tribute to the enormous contribution that Margareta had made to the scientific and clinical understanding of VWD. This sentiment was shared by all present, including Gerda S, the non-affected sister of the index case, Hjördis S.
| CON CLUS IONS
The Fifth Åland Island meeting was a great success as were the previous meetings on these beautiful islands. The soul of the meeting is to convene a nice blend of international leaders in the field of VWD and younger, interested and motivated physicians. The scientific agenda is translational going from molecular genetics and molecules via laboratory issues and pharmacokinetics to epidemiology and clinical challenges, and, of course, history. The meeting has a high scientific standard with plenty of room for discussions and networking.
However, there is also another dimension that is unique: a visit to
Hjördis' house and graveyard gave a fundament for those who contribute to future research and development in the understanding and treatment of VWD.
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